| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 13.82 | 4.4% | 38.2% |
| Total Income | 13.82 | 4.4% | 38.2% |
| Expenditure | 22.04 | 18.2% | 3.1% |
| PBT | -22.86 | 183.6% | 68.7% |
| Net Profit | -22.86 | 183.6% | 68.7% |
| OPM | -59.51% | 30.40pp | |
| NPM | — | ||
| EPS | -0.18 | 157.1% | 28.6% |
Aquestive Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
12 Aug 2026 · 12 Aug, 1:44 am
Summary
Aquestive Therapeutics announced its financial results for the second quarter ended June 30, 2026, reporting a 38% increase in total revenues to $13.8 million, driven by higher manufacture and supply revenue and license and royalty revenue. The company's net loss widened to $22.9 million, or $0.18 per share, from $13.5 million, or $0.14 per share, in the prior year quarter, largely due to a one-time loss on extinguishment of debt. However, the non-GAAP adjusted EBITDA loss improved to $5.2 million from $9.3 million in the prior year quarter. Management highlighted progress on the Anaphylm™ program, with successful completion of key studies and a planned NDA resubmission in Q3 2026.
Key Highlights
- 1
Aquestive Therapeutics reported total revenues increased to $13.8 million in the second quarter of 2026 from $10.0 million in the second quarter of 2025, a 38% increase.
- 2
Manufacture and supply revenue increased to $11.9 million in Q2 2026 from $9.6 million in Q2 2025, primarily due to increases in Suboxone revenues.
- 3
License and royalty revenue increased to $1.3 million in Q2 2026 from $0.8 million in Q2 2025, primarily due to royalty revenue from Zevra.
- 4
Research and development expenses decreased to $4.0 million in Q2 2026 from $4.1 million in Q2 2025.
- 5
Selling, general and administrative expenses increased to $14.1 million in Q2 2026 from $12.7 million in Q2 2025, primarily due to higher legal fees and severance costs.
- 6
Aquestive's net loss for the second quarter of 2026 was $22.9 million, or $0.18 per share, compared to a net loss of $13.5 million, or $0.14 per share, in Q2 2025.
- 7
Non-GAAP adjusted EBITDA loss was $5.2 million in Q2 2026, an improvement from a loss of $9.3 million in Q2 2025.
Management Comments
Daniel Barber
The epinephrine rescue market continues to grow and remains available for conversion from older medical device technology including autoinjectors. As we bring Anaphylm to market, if approved by the FDA, we believe we can be instrumental in driving conversion in the allergist office and, ultimately, the broader market. As we prepare to resubmit our application to the FDA in the coming weeks, our full attention will be to prepare for a focused, allergist-first launch of Anaphylm as quickly as possible, if approved by the FDA. In the meantime, our medical affairs team continues to interact with the allergy community on a daily basis. We also continue to expand our understanding of our AdrenaVerse epinephrine prodrug platform and the opportunity it presents. Controlling the absorption and release of epinephrine allows us to target a variety of indications, especially in dermatological indications such as atopic dermatitis. The well-documented ability of epinephrine to lower histamine release through stabilizing mast cells while also downregulating key inflammatory components of atopic dermatitis creates the potential for a compelling product profile. Although AQST-108 is still in early-stage development, we are encouraged by the emerging data and plan on continuing to advance the program as we look towards 2027.
Informational and educational content only. Not investment advice.